Content & Events

What's New At Scorpius

October 1, 2024

Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model

Scorpius announces the launch of Scorpius Ventures, a new business unit designed to support emerging biotech companies with a flexible American onshoring model.

November 19, 2024

Scorpius' Ania Szymanska Featured in Pharmaceutical Technology’s February 2024 E-book

Scorpius BioManufacturing's Site Head of Quality, Ania Szymanska shares her expertise on how to evaluate a CDMO’s commitment to quality in Pharmaceutical Technology’s February 2024 E-book.

Brochure: Comprehensive Capabilities from Discovery to Commercial Manufacturing

Meeting the Needs of Small-Volume Mammalian Cell Culture Manufacturing

Bridging the gap in small-volume production of biologics with mammalian cell culture.

Live From CPHI with Scorpius' Joe Payne

Scorpius' President & COO Joe Payne, #LiveWithChaudhrey interview at CPHI Milan 2024.

October 22, 2024

CPHI 2024 Wrap-up

Scorpius BioManufacturing CPHI Milan 2024 wrap-up video.

October 14, 2024

Scorpius Holdings Selected to Join Medical CBRN Defense Consortium

Scorpius announces that it has been selected to join Medical CBRN Defense Consortium to advance medical countermeasures against chemical, biological, radiological, and nuclear threats.

October 3, 2024

Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium

Scorpius announces that it has been accepted into the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a part of the National Biopharmaceutical Manufacturing Partnership.

September 10, 2024

Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA

Scorpius announces that it has been selected as a member of the Biomedical Advanced Research and Development Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV).

September 10, 2024

The Rapidly Evolving Landscape of Contract Biologics Manufacturing

In this 15-minute webcast, biopharma industry veteran Joe Payne, President & COO of Scorpius BioManufacturing, explains his take on the contract biologics manufacturing industry.

September 9, 2024

Outsourced Pharma Capacity Update

This 15-minute presentation includes a virtual tour of Scorpius’ process development lab, analytical and QC lab, and some of our cGMP mammalian manufacturing areas.

September 9, 2024

BIO 2024 Wrap-up

Scorpius BioManufacturing 2024 BIO International Convention wrap-up video.

We're Scorpius, a boutique biologics CDMO.

Scorpius BioManufacturing Facility Overview

Take a look into Scorpius' CDMO facilities in San Antonio, TX.

BIO 2024 Lego QC Lab Part 1

Scorpius is partnering with BrevisRefero to build a quality control lab made entirely out of lego bricks for BIO 2024.

Joe Payne PharmTech Interview - DCAT 2024

Q&A with Scorpius' President and COO Joe Payne.

NightHawk Biosciences Completes Name Change to Scorpius Holdings

NightHawk Biosciences announced its name change to Scorpius Holdings, Inc., to better reflect the company’s successful shift into a pure-play, large molecule biomanufacturing CDMO.

February 6, 2024

Scorpius BioManufacturing Announces Joe Payne as President and Chief Operating Officer

Scorpius BioManufacturing, a biologics contract development and manufacturing organization (CDMO), promoted Joe Payne to President and COO.

February 1, 2024

From frustration to innovation: a CDMO’s mission to empower emerging biotechs

Capacity, capacity, capacity. This seems to be all the industry talks about. A global pandemic magnified the need for more biologics manufacturing capacity. Capacity, however, isn’t the whole story.

October 20, 2023

Does Your Biologics CDMO Truly Have a Culture of Quality?

Joe Payne, Scorpius' President & COO, shares what 20+ years in pharma has taught him about creating a culture of quality.

Scorpius Expands Leadership Team With New VP, Manufacturing Operations

Scorpius BioManufacturing, a biologics contract development and manufacturing organization (CDMO), expanded its leadership to include Matthew R. LeClair.

Scorpius Corporate Video

Learn more about our boutique biologics facility in San Antonio, TX

Biologics Outsourcing: Decision Drivers and Key Considerations

A recent survey of 100 decision makers at innovative biologics companies revealed 57% of respondents believe their companies’ outsourcing activities will increase over the next two years, while a furt...

An Experienced CDMO Can Be a Differentiator in the Rapidly Growing Biologics Market

By providing end-to-end services — including secure supply chains — CRO/CDMOs, like Scorpius BioManufacturing can help biologics developers meet accelerated timelines and establish a real competitive ...

January 31, 2023

The Bioanalytical Development Journey

Biopharma companies outsource pharmaceutical development and manufacturing from discovery, bioanalytical testing, qualification to validation.

Evaluating Single-Use Technologies for Biomanufacturing

Single-use technologies (SUTs) are ideal for multiproduct facilities producing smaller volumes of materials.

November 22, 2021

ABC: Analytics for Biomanufacturing and Clinical Trials of Biomanufactured Products

Samir Lakhashe, Director, Bioanalysis, discusses assay categorization, the company's growing toolbox, predictions for the future, and what scientists who want to join the growing team should know, wit...

October 15, 2021